Chimeric antigen receptor T-cell therapy

Research output: Contribution to journalArticle


Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma treatment is setting the stage for what is possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, and costs associated with CAR T-cell therapy. To begin to address these issues, NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This report describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.

Original languageEnglish (US)
Pages (from-to)1093-1106
Number of pages14
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number9
Publication statusPublished - Sep 1 2018


ASJC Scopus subject areas

  • Oncology

Cite this

Ogba, N., Arwood, N. M., Bartlett, N. L., Bloom, M., Brown, P. A., Brown, C., ... Rosen, S. T. (2018). Chimeric antigen receptor T-cell therapy. JNCCN Journal of the National Comprehensive Cancer Network, 16(9), 1093-1106.